2024
Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis
Park D, Hu J, Campbell G, Goldwag K, Kelsey M, Altin S, Gallegos-Kattán C, Nanna M. Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis. Journal Of The Society For Cardiovascular Angiography & Interventions 2024, 3: 101859. PMID: 39131993, PMCID: PMC11307649, DOI: 10.1016/j.jscai.2024.101859.Peer-Reviewed Original ResearchMonths of DAPTDuration of dual antiplatelet therapyNet adverse clinical eventsType 2 diabetes mellitusDual antiplatelet therapyAcute coronary syndromeRandomized controlled trialsSensitivity analysis of trialsPercutaneous coronary interventionCoronary interventionNo significant differenceAntiplatelet therapyAnalysis of trialsCoronary syndromeControlled trialsMeta-analysis of patientsStent thrombosisMeta-analysisDAPT durationClinicians greater flexibilityStudy-level meta-analysisOptimal duration of dual antiplatelet therapyHigher risk of adverse eventsPostpercutaneous coronary interventionRisk of adverse eventsClinical Interpretation of Serum Troponin in the Era of High-Sensitivity Testing
Maayah M, Grubman S, Allen S, Ye Z, Park D, Vemmou E, Gokhan I, Sun W, Possick S, Kwan J, Gandhi P, Hu J. Clinical Interpretation of Serum Troponin in the Era of High-Sensitivity Testing. Diagnostics 2024, 14: 503. PMID: 38472975, PMCID: PMC10930800, DOI: 10.3390/diagnostics14050503.Peer-Reviewed Original ResearchAcute coronary syndromeTn elevationCoronary syndromeTreatment of acute coronary syndromesNon-cardiac etiologyManagement of myocardial injuryEvaluation of patientsHigh-sensitivity assaySerum troponinHighly sensitive testPrognostic implicationsCardiac troponinMyocardial injuryPhysical examMyocardial ischemiaPoor specificityLaboratory dataClinical judgmentClinical interpretationTroponinSyndromeAnalytical sensitivityTN measurementsPresentationElevation
2022
Impact of cardiac and noncardiac cirrhosis on coronary revascularization outcomes from the National Inpatient Sample, 2016 to 2018
Park D, An S, Warraich M, Aldeen Z, Maghari I, Khanal S, Arif A, Almoghrabi A. Impact of cardiac and noncardiac cirrhosis on coronary revascularization outcomes from the National Inpatient Sample, 2016 to 2018. Baylor University Medical Center Proceedings 2022, 36: 195-200. PMID: 36876247, PMCID: PMC9980685, DOI: 10.1080/08998280.2022.2139989.Peer-Reviewed Original ResearchCoronary artery bypass graftingCoronary artery bypass grafting cohortIn-hospital mortalityPercutaneous coronary interventionAcute coronary syndromeHigher in-hospital mortalityNational Inpatient SampleCardiac cirrhosisCoronary revascularizationAssociated with higher in-hospital mortalityInpatient SamplePercutaneous coronary intervention cohortArtery bypass graftingPeriprocedural morbiditySignificant comorbiditiesCoronary syndromeLiver cirrhosisBypass graftingRevascularization outcomesPrimary outcomeCirrhosisNo cirrhosisCoronary interventionPatientsScore matchingShortening the duration of dual antiplatelet therapy after percutaneous coronary intervention for acute coronary syndrome: A systematic review and meta-analysis
Park DY, Wang P, An S, Grimshaw AA, Frampton J, Ohman EM, Rao SV, Nanna MG. Shortening the duration of dual antiplatelet therapy after percutaneous coronary intervention for acute coronary syndrome: A systematic review and meta-analysis. American Heart Journal 2022, 251: 101-114. PMID: 35654162, PMCID: PMC10904033, DOI: 10.1016/j.ahj.2022.05.019.Peer-Reviewed Original ResearchConceptsMonths of DAPTHazard ratioIschemic eventsDuration of DAPTSelect patient characteristicsDual antiplatelet therapyAcute coronary syndromeCoronary artery lesionsPercutaneous coronary interventionConfidence intervalsAssociation of outcomesRandom-effects modelComprehensive literature searchMeta-regression analysisMajor bleedingAntiplatelet therapyCoronary syndromeArtery lesionsCoronary interventionControlled TrialsPatient characteristicsPrespecified outcomesGreater proportionSimilar efficacySystematic review